# A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19

> **NCT06039163** · PHASE1 · COMPLETED · sponsor: **Huahui Health** · enrollment: 37 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** HH-120
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06039163
- **Lead sponsor:** Huahui Health
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-16
- **Primary completion:** 2022-10-10
- **Final completion:** 2022-10-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06039163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06039163, "A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT06039163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*